Romania · Delayed Price · Currency is RON Antibiotice Statistics
Total Valuation
Antibiotice has a market cap or net worth of RON 1.68 billion. The enterprise value is 1.92 billion.
| Market Cap | 1.68B |
| Enterprise Value | 1.92B |
Important Dates
The next estimated earnings date is Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | Sep 25, 2025 |
Share Statistics
Antibiotice has 671.34 million shares outstanding. The number of shares has decreased by -0.06% in one year.
| Current Share Class | 671.34M |
| Shares Outstanding | 671.34M |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | +0.07% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 1.08% |
| Float | 227.92M |
Valuation Ratios
The trailing PE ratio is 19.26.
| PE Ratio | 19.26 |
| Forward PE | n/a |
| PS Ratio | 2.51 |
| PB Ratio | 1.79 |
| P/TBV Ratio | 1.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 222.73 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.63, with an EV/FCF ratio of -20.15.
| EV / Earnings | 22.06 |
| EV / Sales | 2.87 |
| EV / EBITDA | 12.63 |
| EV / EBIT | 18.71 |
| EV / FCF | -20.15 |
Financial Position
The company has a current ratio of 2.27, with a Debt / Equity ratio of 0.27.
| Current Ratio | 2.27 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 1.67 |
| Debt / FCF | -2.67 |
| Interest Coverage | 21.59 |
Financial Efficiency
Return on equity (ROE) is 9.66% and return on invested capital (ROIC) is 5.90%.
| Return on Equity (ROE) | 9.66% |
| Return on Assets (ROA) | 4.76% |
| Return on Invested Capital (ROIC) | 5.90% |
| Return on Capital Employed (ROCE) | 8.88% |
| Revenue Per Employee | 493,966 |
| Profits Per Employee | 64,257 |
| Employee Count | 1,357 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 1.26 |
Taxes
In the past 12 months, Antibiotice has paid 5.85 million in taxes.
| Income Tax | 5.85M |
| Effective Tax Rate | 6.29% |
Stock Price Statistics
The stock price has decreased by -19.35% in the last 52 weeks. The beta is 0.19, so Antibiotice's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -19.35% |
| 50-Day Moving Average | 2.48 |
| 200-Day Moving Average | 2.36 |
| Relative Strength Index (RSI) | 50.98 |
| Average Volume (20 Days) | 174,126 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Antibiotice had revenue of RON 669.82 million and earned 87.13 million in profits. Earnings per share was 0.13.
| Revenue | 669.82M |
| Gross Profit | 418.89M |
| Operating Income | 102.74M |
| Pretax Income | 92.98M |
| Net Income | 87.13M |
| EBITDA | 152.19M |
| EBIT | 102.74M |
| Earnings Per Share (EPS) | 0.13 |
Balance Sheet
The company has 10.35 million in cash and 254.46 million in debt, giving a net cash position of -244.11 million or -0.36 per share.
| Cash & Cash Equivalents | 10.35M |
| Total Debt | 254.46M |
| Net Cash | -244.11M |
| Net Cash Per Share | -0.36 |
| Equity (Book Value) | 939.43M |
| Book Value Per Share | 1.40 |
| Working Capital | 351.38M |
Cash Flow
In the last 12 months, operating cash flow was 7.54 million and capital expenditures -102.96 million, giving a free cash flow of -95.43 million.
| Operating Cash Flow | 7.54M |
| Capital Expenditures | -102.96M |
| Free Cash Flow | -95.43M |
| FCF Per Share | -0.14 |
Margins
Gross margin is 62.54%, with operating and profit margins of 15.34% and 13.01%.
| Gross Margin | 62.54% |
| Operating Margin | 15.34% |
| Pretax Margin | 13.88% |
| Profit Margin | 13.01% |
| EBITDA Margin | 22.72% |
| EBIT Margin | 15.34% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 0.82%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 0.82% |
| Dividend Growth (YoY) | -75.21% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 64.88% |
| Buyback Yield | 0.06% |
| Shareholder Yield | 0.88% |
| Earnings Yield | 5.19% |
| FCF Yield | -5.69% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 13, 2013. It was a forward split with a ratio of 1.1819213313.
| Last Split Date | May 13, 2013 |
| Split Type | Forward |
| Split Ratio | 1.1819213313 |
Scores
Antibiotice has an Altman Z-Score of 3.79 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.79 |
| Piotroski F-Score | 4 |